Adding eganelisib to nivolumab shows survival benefit in bladder cancer
The survival benefit in patients with PD-L1–negative tumors mirrored the benefit in the overall study population.
The survival benefit in patients with PD-L1–negative tumors mirrored the benefit in the overall study population.
Real-world data showed routine use of darolutamide regimens in community urology practice for patients with metastatic hormone-sensitive prostate cancer.
Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
Sarah P. Psutka, MD, MSc, shares the rationale for the “Get Moving Trial,” exploring at-home prehabilitation for patients with muscle-invasive bladder cancer.
UGN-101 showed efficacy in a broad population of patients with upper tract urothelial cancer and recurrence-free survival rates were high among patients who responded to…
“So, in the MoonRISe-1 study, we’re studying the efficacy of TAR-210 to prevent recurrence within the bladder by inserting the TAR-210 in the bladder every…
Patients receiving PUL experienced improvements of 8.6 and (39.1%) and 10 (46.8%) in IPSS total score.
There were no adverse events, such as penile bruising, swelling, edema, allergy, or penile fracture, observed in patients treated with shockwave therapy plus platelet rich…
“[The] NURE-Combo trial provided insights into the potential value of expanding chemotherapy combinations with immune checkpoint [inhibitors] in muscle-invasive disease,” said Chiara Mercinelli, MD.
Angela B. Smith, MD, MS, highlights key takeaways from the session, “Time Efficiency and Productivity Hacks for the Busy Urologist,” which was presented at the…
“BCG worked well enough that we could give it to patients and it worked pretty well. But having the shortage, I think, has ultimately led…